Results 41 to 50 of about 2,765,640 (158)

Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload

JACC: Basic to Translational Science, 2020
Summary: Activated factor X is a key component of the coagulation cascade, but whether it directly regulates pathological cardiac remodeling is unclear.
Xinji Guo, PhD, Mikhail A. Kolpakov, MD, PhD, Bahman Hooshdaran, PhD, William Schappell, BS, Tao Wang, MD, PhD, Satoru Eguchi, MD, PhD, Katherine J. Elliott, PhD, Douglas G. Tilley, PhD, A. Koneti Rao, MD, Patricia Andrade-Gordon, PhD, Matthew Bunce, PhD, Chintala Madhu, PhD, Steven R. Houser, PhD, Abdelkarim Sabri, PhD   +13 more
doaj   +1 more source

The X Factor in Understanding Listening Comprehension Skill

English Education Journal: Jurnal Pengembangan Pendidikan dan Pengembangan Pengajaran Bahasa, 2019
This research was aimed to find out factors affecting students’ challenges in listening comprehension as perceived by students at SMAN 1 Calang. This is a descriptive qualitative study.
Bustami Usman, Chairina Nasir, Tiya Akmalia   +2 more
doaj  

Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis

Journal of Investigative Medicine High Impact Case Reports, 2019
Acquired factor X (FX) deficiency is a rare but serious complication of primary amyloidosis, presumably caused by the binding of amyloid proteins to the clotting factors.
Siroj Dejhansathit MD, Attaya Suvannasankha MD   +1 more
doaj   +1 more source

Severe Factor X deficiency and successful pregnancy outcome: A rare case

Journal of Applied Hematology, 2018
Factor X (FX) is a Vitamin K-dependent, serine protease produced by the liver that serves pivotal role as the first enzyme in the so-called common pathway of coagulation cascade in fibrin formation.
Debraj Basu, Prakas Kumar Mandal, Mostafa Kamal   +2 more
doaj   +1 more source

Factor XI localization in human deep venous thrombus and function of activated factor XI on venous thrombus formation and hemostasis

Research and Practice in Thrombosis and Haemostasis
Background: Novel anticoagulants targeting coagulation factor (F)XI/activated FXI (FXIa) are currently under development. However, whether FXI is present in human deep vein thrombosis (DVT) and whether FXIa and activated FX (FXa) play different roles in ...
Nobuyuki Oguri, Toshihiro Gi, Eriko Nakamura, Kazunari Maekawa, Eiji Furukoji, Hoshimi Okawa, Sho Kouyama, Saki Horiuchi, Akira Sawaguchi, Tatefumi Sakae, Minako Azuma, Yujiro Asada, Atsushi Yamashita   +12 more
doaj   +1 more source

Anticoagulation in atrial fibrillation with factor X deficiency—A management dilemma

Clinical Case Reports, 2018
Key Clinical Message Factor X (FX) deficiency is a rare bleeding disorder. There is currently no clear guideline or recommendation for the appropriate selection of anticoagulation and management of patients with FX deficiency who require anticoagulation.
Jian Liang Tan, Kah Poh Loh, Danielle Fortuna, Arezoo Ghaneie   +3 more
doaj   +1 more source

Orphan Three-Finger Toxins Bind at Tissue Factor–Factor VIIa Interface to Inhibit Factor X Activation: Identification of Functional Site by Docking

TH Open, 2018
Three-finger toxins (3FTxs) contribute to toxicity of venomous snakes belonging to the family Elapidae. Currently, functions of a considerable proportion of 3FTxs are still unknown.
Manisha Choudhury, Ryan J. R. McCleary, R. Manjunatha Kini, Devadasan Velmurugan   +3 more
doaj   +1 more source

Management of Acquired Factor X Deficiency Caused by In Vitro Non-neutralizing Anti-factor X Autoantibodies with Pre-emptive Corticosteroid Therapy. [PDF]

Intern Med, 2023
Onishi A, Shimura Y, Nakamura T, Souri M, Osaki T, Mizutani S, Tsukamoto T, Kobayashi T, Ichinose A, Kuroda J.   +9 more
europepmc   +1 more source

Genotype x environment interaction in cassava multi-environment trials via analytic factor.

PLoS ONE
The variability in genetic variance and covariance due to genotype × environment interaction (G×E) can hinder genotype selection accuracy, especially for complex traits.
Juraci Souza Sampaio Filho, Isadora Cristina Martins Oliveira, Maria Marta Pastina, Marcos de Souza Campos, Eder Jorge de Oliveira   +4 more
doaj   +1 more source

Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X

Research and Practice in Thrombosis and Haemostasis
Background: Persons with hemophilia A (HA) and inhibitors undergoing emicizumab prophylaxis require bypassing agents when breakthrough bleeding occurs.
Mitsumasa Osuna, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami   +4 more
doaj   +1 more source